#Cambridge #United Kingdom #ophthalmology #Diabetic Retinopathy #Foventa

Exonate Rebrands as Foventa Therapeutics

In a significant strategic shift, Exonate Limited, a clinical-stage company focusing on ophthalmology, announced its rebranding as Foventa Therapeutics on September 1, 2026. This new identity signals a pivotal transition from their foundational science towards patient-centric outcomes, particularly in the realm of diabetic eye care.

The rebranding reflects the company's commitment to clinical development for non-proliferative diabetic retinopathy (NPDR), a common sight-threatening condition among diabetics. The name 'Foventa' is inspired by the 'fovea'—the part of the retina responsible for sharp vision—juxtaposed with the company's motto: "Simply Sharper." This phrase encapsulates both their vision and their innovative approach to treatment delivery.

Foventa's lead product, FOV407, is a topical eye drop that aims to combat the damaging effects of diabetic retinopathy. Early clinical trials highlighted FOV407's impressive ability to suppress harmful vascular leakage in the eyes, indicating a promising future for patients suffering from this condition. The shift from Exonate to Foventa was articulated by CEO Olav Hellebø, who emphasized the importance of making scientific advancements accessible to patients. “A molecule only matters if it reaches patients,” Hellebø stated, underscoring the company's mission to develop treatment options for those at risk of vision loss due to diabetic retinopathy.

Chairman Rafiq Hasan supported this new direction, commenting on the importance of transitioning from scientific discovery to clinical implementation. Foventa Therapeutics aims to fill a critical gap in the treatment landscape for NPDR, which remains largely untreated today. With FOV407, the company has selected a small molecule that effectively targets the vascular endothelial growth factor (VEGF) pathway, known to drive diabetic eye diseases. From over 1,000 designed molecules, FOV407 was selected for its optimal retinal penetration, potency, and selectivity.

As the company prepares for a Phase IIb study of FOV407, they are working closely with regulatory bodies such as the US Food and Drug Administration to refine their approach. The design of this upcoming trial has already been vetted through a Type C meeting with the FDA, indicating a solid strategic pathway forward.

Foventa Therapeutics thus emerges not merely as a new name but as a beacon of hope for diabetic patients, promising a future wherein effective treatments are not a luxury but a standard. Their commitment to non-invasive delivery methods aligns with a growing trend in healthcare to prioritize patient comfort and ease of access, reaffirming their goal of preventing blindness amongst diabetic individuals globally. For more insights into their journey and innovations, additional information can be found on their website at Foventa.com.